Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure: Journal of Hepatology

NAVIGATORE-Lombardia and Veneto Study Groups, E. Degasperi, A. Spinetti, A. Lombardi, S. Landonio, M.C. Rossi, L. Pasulo, P. Pozzoni, A. Giorgini, P. Fabris, A. Romano, L. Lomonaco, M. Puoti, M. Vinci, F. Gatti, G. Carolo, A. Zoncada, P. Bonfanti, F.P. Russo, A. AghemoA. Soria, R. Centenaro, F. Maggiolo, P. Rovere, F. Pasin, V. Paon, G. Faggiano, A. Vario, G. Grossi, R. Soffredini, C. Carriero, S. Paolucci, F. Noventa, A. Alberti, P. Lampertico, S. Fagiuoli

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)1106-1115
Number of pages10
JournalJ. Hepatol.
Issue number6
Publication statusPublished - 2019


  • Direct-acting antivirals
  • HCV
  • RAS
  • Resistance
  • Retreatment
  • Sofosbuvir

Cite this